#China #Shanghai #Virax Biolabs #ImmuneSelect

Virax Biolabs Expands Distribution Network in China

Virax Biolabs Group Limited (NASDAQ: VRAX), a leader in the biotechnology sector focused on immune response detection, has announced strategic distribution agreements through its Chinese subsidiary, Shanghai Xitu Consulting Co., Ltd. The company has appointed three distributors to enhance the reach of its ImmuneSelect research-use immune profiling products across mainland China.

The selected distributors are AmyJet Scientific Inc., Jiangsu Real-Gen Biotechnology Co., Ltd., and Zhixi (Shanghai) Biotechnology Co., Ltd. This initiative marks a significant step in Virax's commercial strategy, building on the initial successes of ImmuneSelect product sales within the region.

Focus on ImmuneSelect Portfolio

ImmuneSelect is designed explicitly for research purposes, distinguishing it from ViraxImmune™, which is a diagnostic platform currently under development. With the new agreements, the distributors will facilitate the purchase and resale of ImmuneSelect products within their designated markets, while also managing local sales activities and customer training. This arrangement allows Virax to concentrate on product supply, documentation, and technical support, ensuring a comprehensive service offering to its partners.

These agreements are set to create non-exclusive distribution channels across crucial territories, including Beijing, Shanghai, Hubei, Jiangsu, Anhui, and Shandong. Key biotechnology hubs such as Beijing's Zhongguancun Life Science Park, Zhangjiang Pharma Valley in Shanghai, Suzhou's BioBAY, and Wuhan's BioLake will be integral to the distribution strategy, aiming to target significant research customer segments.

Distributors Profile

1. AmyJet Scientific Inc. - With a strong presence in Beijing, Shanghai, and Hubei, AmyJet has established relationships with over 200 international life sciences suppliers. The company specializes in ELISpot and other immunology research reagents.

2. Jiangsu Real-Gen Biotechnology Co., Ltd. - Operating in Suzhou, Nanjing, Hefei, and Jinan, Jiangsu Real-Gen will focus on serving academic and biopharmaceutical research customers in Jiangsu, Anhui, and Shandong. The company offers research instruments and reagents across various biological disciplines.

3. Zhixi (Shanghai) Biotechnology Co., Ltd. - Leveraging its relationship with common ownership at Shanghai KEL Biotech, Zhixi will cater to academic channels in Shanghai, enhancing local sales and support for ImmuneSelect products.

The initial focus for these distributors will be on ELISpot assay plates and antigen-specific peptide pools, which are utilized in crucial research fields such as infectious diseases, vaccine development, and cellular immunity studies.

Strategic Importance of China

James Foster, the CEO of Virax Biolabs, emphasized the importance of the Chinese market for ImmuneSelect. The country exhibits substantial activity in biotechnology and academic research related to cellular immunology and vaccine development. By establishing these partnerships, Virax aims to leverage local distribution networks to foster commercial growth while converting product evaluations into consistent orders.

The goal remains to build recurring reagent sales through effective local engagement, all while maintaining an efficient and disciplined commercial model. This approach underpins Virax's broader vision of addressing critical challenges in immune response detection and developing effective diagnostic solutions for conditions like Long COVID and other immune dysfunction disorders.

As Virax Biolabs continues to expand its footprint in the Chinese biopharmaceutical sector, it remains committed to enhancing its product offerings and customer relationships while driving innovation in immune response technologies. For more details on the company and its offerings, visit Virax Biolabs.